A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy.
CDK4/6 inhibitors
COVID19
metastatic breast cancer
palbociclib
pneumonia
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
04
2020
accepted:
29
05
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
We describe the first case report of a patient with COVID19 infection and metastatic breast cancer, while on systemic therapy with a CDK4/6 inhibitor. The patient had unique disease course, characterized with delayed symptomatology. The case highlights novel findings and stress careful and extended follow-up during COVID19 infection in patients taking biologic therapies affecting the immune system.
Identifiants
pubmed: 32582559
doi: 10.3389/fonc.2020.01085
pmc: PMC7295974
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1085Informations de copyright
Copyright © 2020 Grinshpun, Merlet, Fruchtman and Nachman.
Références
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Nat Rev Drug Discov. 2017 Mar 30;16(4):229
pubmed: 28356596
Breast Cancer Res. 2016 Jun 28;18(1):67
pubmed: 27349747
NPJ Breast Cancer. 2018 Jun 26;4:14
pubmed: 29951582
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Oncologist. 2016 Oct;21(10):1165-1175
pubmed: 27368881
Lancet Oncol. 2020 Feb;21(2):250-260
pubmed: 31859246
Clin Breast Cancer. 2020 Apr;20(2):e192-e195
pubmed: 32088132
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
JAMA. 2020 Feb 7;:
pubmed: 32031570
Ann Rheum Dis. 2020 May;79(5):667-668
pubmed: 32241793
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093